Edwards Lifesciences Co. (NYSE:EW) Shares Sold by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd reduced its holdings in Edwards Lifesciences Co. (NYSE:EW) by 18.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,668,843 shares of the medical research company’s stock after selling 604,573 shares during the quarter. Edwards Lifesciences makes up 0.9% of AustralianSuper Pty Ltd’s portfolio, making the stock its 24th biggest holding. AustralianSuper Pty Ltd owned approximately 0.45% of Edwards Lifesciences worth $197,574,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Asset Planning Inc acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $1,993,000. Banque Pictet & Cie SA raised its holdings in shares of Edwards Lifesciences by 106.2% during the 4th quarter. Banque Pictet & Cie SA now owns 156,968 shares of the medical research company’s stock valued at $11,620,000 after buying an additional 80,851 shares during the period. V Square Quantitative Management LLC raised its stake in shares of Edwards Lifesciences by 2.3% during the fourth quarter. V Square Quantitative Management LLC now owns 15,374 shares of the medical research company’s stock valued at $1,138,000 after purchasing an additional 348 shares during the period. Bogart Wealth LLC lifted its holdings in Edwards Lifesciences by 38.2% in the 4th quarter. Bogart Wealth LLC now owns 92,768 shares of the medical research company’s stock worth $6,868,000 after buying an additional 25,657 shares in the last quarter. Finally, Asset Management One Co. Ltd. boosted its position in Edwards Lifesciences by 1.0% in the 4th quarter. Asset Management One Co. Ltd. now owns 241,818 shares of the medical research company’s stock valued at $18,294,000 after buying an additional 2,426 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 6,500 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,555,402. The trade was a 12.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,750 shares of company stock worth $1,564,255. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Up 0.2 %

Shares of NYSE:EW opened at $75.96 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a 50 day moving average price of $72.51 and a 200 day moving average price of $69.36. The stock has a market capitalization of $44.80 billion, a price-to-earnings ratio of 10.96, a PEG ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of a number of analyst reports. Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Barclays raised their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday. Citigroup boosted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.